{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:33:08Z","timestamp":1767853988939,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-04554-8","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:24:08Z","timestamp":1764653048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study on the heteroresistance of carbapenem-resistant\u00a0Klebsiella pneumoniae to Tigecycline and\u00a0Polymyxin B and antibacterial activity of combined drugs in vitro"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-7818","authenticated-orcid":false,"given":"Yulan","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-8447","authenticated-orcid":false,"given":"Haifang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-3800","authenticated-orcid":false,"given":"Yuanhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"4554_CR1","doi-asserted-by":"publisher","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","DOI":"10.1016\/S0140-6736(21)02724-0"},{"issue":"4","key":"4554_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cmi.2024.01.014","volume":"30","author":"Q Luo","year":"2024","unstructured":"Luo Q, Xu L, Wang Y, Fu H, Xiao T, Yu W, et al. Clinical relevance, mechanisms, and evolution of polymyxin B heteroresistance carbapenem-resistant Klebsiella pneumoniae: a genomic, retrospective cohort study. Clin Microbiol Infect. 2024;30(4):507\u201314. https:\/\/doi.org\/10.1016\/j.cmi.2024.01.014.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4554_CR3","doi-asserted-by":"publisher","first-page":"e3001346","DOI":"10.1371\/journal.pbio.3001346","volume":"19","author":"VI Band","year":"2021","unstructured":"Band VI, Weiss DS. Heteroresistance to beta-lactam antibiotics may often be a stage in the progression to antibiotic resistance. PLoS Biol. 2021;19(7):e3001346. https:\/\/doi.org\/10.1371\/journal.pbio.3001346.","journal-title":"PLoS Biol"},{"issue":"1","key":"4554_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/CMR.00058-14","volume":"28","author":"OM El-Halfawy","year":"2015","unstructured":"El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28(1):191\u2013207. https:\/\/doi.org\/10.1128\/CMR.00058-14.","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"4554_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","volume":"17","author":"DI Andersson","year":"2019","unstructured":"Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17(8):479\u201396. https:\/\/doi.org\/10.1038\/s41579-019-0218-1.","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"4554_CR6","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s11756-021-00820-y","volume":"76","author":"A Manjunath","year":"2021","unstructured":"Manjunath A, Thumu SCR, Kumar S, Halami PM. Bacterial heteroresistance: an evolving novel way to combat antibiotics. Biologia. 2021;76(10):3029\u201341. https:\/\/doi.org\/10.1007\/s11756-021-00820-y.","journal-title":"Biologia"},{"key":"4554_CR7","doi-asserted-by":"publisher","first-page":"868991","DOI":"10.3389\/fmicb.2022.868991","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Ma X, Zhao L, He Y, Yu W, Fu S, et al. Heteroresistance is associated with in vitro regrowth during colistin treatment in Carbapenem-Resistant Klebsiella pneumoniae. Front Microbiol. 2022;13:868991. https:\/\/doi.org\/10.3389\/fmicb.2022.868991.","journal-title":"Front Microbiol"},{"issue":"12","key":"4554_CR8","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1128\/JCM.02129-13","volume":"51","author":"D Landman","year":"2013","unstructured":"Landman D, Salamera J, Quale J. Irreproducible and uninterpretable polymyxin B mics for Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol. 2013;51(12):4106\u201311. https:\/\/doi.org\/10.1128\/JCM.02129-13.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"4554_CR9","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S2666-5247(23)00374-9","volume":"5","author":"T Ozturk","year":"2024","unstructured":"Ozturk T, Weiss DS. Heteroresistance is a cause of discrepant antibiotic susceptibility testing results. Lancet Microbe. 2024;5(4):e312. https:\/\/doi.org\/10.1016\/S2666-5247(23)00374-9.","journal-title":"Lancet Microbe"},{"issue":"6","key":"4554_CR10","doi-asserted-by":"publisher","first-page":"16053","DOI":"10.1038\/nmicrobiol.2016.53","volume":"1","author":"VI Band","year":"2016","unstructured":"Band VI, Crispell EK, Napier BA, Herrera CM, Tharp GK, Vavikolanu K, et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol. 2016;1(6):16053. https:\/\/doi.org\/10.1038\/nmicrobiol.2016.53.","journal-title":"Nat Microbiol"},{"key":"4554_CR11","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.2147\/IDR.S340652","volume":"14","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Han Y, Zhao Z, Gao W, Ma Y, Jiang S, et al. Impact of carbapenem heteroresistance among Multidrug-Resistant ESBL\/AmpC-Producing Klebsiella pneumoniae clinical isolates on antibiotic treatment in experimentally infected mice. Infect Drug Resist. 2021;14:5639\u201350. https:\/\/doi.org\/10.2147\/IDR.S340652.","journal-title":"Infect Drug Resist"},{"key":"4554_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.105162","volume":"160","author":"F Zhang","year":"2021","unstructured":"Zhang F, Ding M, Yan X, Bai J, Li Q, Zhang B, et al. Carbapenem-resistant K. pneumoniae exhibiting clinically undetected amikacin and meropenem heteroresistance leads to treatment failure in a murine model of infection. Microb Pathog. 2021;160:105162. https:\/\/doi.org\/10.1016\/j.micpath.2021.105162.","journal-title":"Microb Pathog"},{"issue":"6","key":"4554_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007726","volume":"15","author":"VI Band","year":"2019","unstructured":"Band VI, Weiss DS. Heteroresistance: a cause of unexplained antibiotic treatment failure? PLoS Pathog. 2019;15(6):e1007726. https:\/\/doi.org\/10.1371\/journal.ppat.1007726.","journal-title":"PLoS Pathog"},{"key":"4554_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03183-4","author":"B Zhai","year":"2024","unstructured":"Zhai B, Liao C, Jaggavarapu S, Tang Y, Rolling T, Ning Y, et al. Antifungal heteroresistance causes prophylaxis failure and facilitates breakthrough Candida parapsilosis infections. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03183-4.","journal-title":"Nat Med"},{"issue":"9","key":"4554_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","volume":"13","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785\u201396. https:\/\/doi.org\/10.1016\/S1473-3099(13)70190-7.","journal-title":"Lancet Infect Dis"},{"key":"4554_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020234","author":"T Karampatakis","year":"2023","unstructured":"Karampatakis T, Tsergouli K, Behzadi P. Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics. 2023. https:\/\/doi.org\/10.3390\/antibiotics12020234.","journal-title":"Antibiotics"},{"key":"4554_CR17","doi-asserted-by":"publisher","first-page":"671153","DOI":"10.3389\/fmicb.2021.671153","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Lin L, Pan Y, Chen J. Characterization of tigecycline-heteroresistant Klebsiella pneumoniae clinical isolates from a Chinese tertiary care teaching hospital. Front Microbiol. 2021;12:671153. https:\/\/doi.org\/10.3389\/fmicb.2021.671153.","journal-title":"Front Microbiol"},{"issue":"4","key":"4554_CR18","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1128\/AAC.06268-11","volume":"56","author":"ZA Qureshi","year":"2012","unstructured":"Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108\u201313. https:\/\/doi.org\/10.1128\/AAC.06268-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4554_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijantimicag.2013.01.020","volume":"41","author":"PC McGovern","year":"2013","unstructured":"McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013;41(5):463\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.01.020.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4554_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.molcel.2019.09.028","volume":"76","author":"L Dewachter","year":"2019","unstructured":"Dewachter L, Fauvart M, Michiels J. Bacterial heterogeneity and antibiotic survival: understanding and combatting persistence and heteroresistance. Mol Cell. 2019;76(2):255\u201367. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.028.","journal-title":"Mol Cell"},{"issue":"1","key":"4554_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","volume":"44","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.01.006.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"4554_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.diagmicrobio.2012.12.004","volume":"75","author":"GE Stein","year":"2013","unstructured":"Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331\u20136. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.12.004.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"4554_CR23","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1128\/AAC.01365-09","volume":"54","author":"ST Micek","year":"2010","unstructured":"Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54(5):1742\u20138. https:\/\/doi.org\/10.1128\/AAC.01365-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4554_CR24","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1128\/AAC.00264-10","volume":"54","author":"Y Cai","year":"2010","unstructured":"Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(9):3998\u20139. https:\/\/doi.org\/10.1128\/AAC.00264-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4554_CR25","doi-asserted-by":"publisher","first-page":"e0126479","DOI":"10.1371\/journal.pone.0126479","volume":"10","author":"C Stein","year":"2015","unstructured":"Stein C, Makarewicz O, Bohnert JA, Pfeifer Y, Kesselmeier M, Hagel S, et al. Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against Multidrug-Resistant clinical Klebsiella pneumonia isolates. PLoS One. 2015;10(6):e0126479. https:\/\/doi.org\/10.1371\/journal.pone.0126479.","journal-title":"PLoS One"},{"issue":"9","key":"4554_CR26","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1128\/AAC.49.9.3903-3909.2005","volume":"49","author":"PA Bradford","year":"2005","unstructured":"Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O\u2019Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother. 2005;49(9):3903\u20139. https:\/\/doi.org\/10.1128\/AAC.49.9.3903-3909.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4554_CR27","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1128\/AAC.49.9.3910-3918.2005","volume":"49","author":"PJ Petersen","year":"2005","unstructured":"Petersen PJ, Bradford PA. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of Tigecycline against recent clinical isolates. Antimicrob Agents Chemother. 2005;49(9):3910\u20138. https:\/\/doi.org\/10.1128\/AAC.49.9.3910-3918.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4554_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119\u201323. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.12.002.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4554_CR29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/IDR.S396609","volume":"16","author":"B Dan","year":"2023","unstructured":"Dan B, Dai H, Zhou D, Tong H, Zhu M. Relationship between drug resistance characteristics and biofilm formation in Klebsiella pneumoniae strains. Infect Drug Resist. 2023;16:985\u201398. https:\/\/doi.org\/10.2147\/IDR.S396609.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"4554_CR30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jac\/dkr007","volume":"66","author":"G Meletis","year":"2011","unstructured":"Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011;66(4):946\u20137. https:\/\/doi.org\/10.1093\/jac\/dkr007.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4554_CR31","doi-asserted-by":"publisher","first-page":"e0015221","DOI":"10.1128\/Spectrum.00152-21","volume":"9","author":"Y Tian","year":"2021","unstructured":"Tian Y, Zhang Q, Wen L, Chen J. Combined effect of polymyxin B and Tigecycline to overcome heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae. Microbiol Spectr. 2021;9(2):e0015221. https:\/\/doi.org\/10.1128\/Spectrum.00152-21.","journal-title":"Microbiol Spectr"},{"key":"4554_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.dnarep.2014.09.009","volume":"24","author":"AB Williams","year":"2014","unstructured":"Williams AB. Spontaneous mutation rates come into focus in Escherichia coli. DNA Repair (Amst). 2014;24:73\u20139. https:\/\/doi.org\/10.1016\/j.dnarep.2014.09.009.","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"4554_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/s0021-9258(18)65573-5","volume":"208","author":"GB Elion","year":"1954","unstructured":"Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives. J Biol Chem. 1954;208(2):477\u201388. https:\/\/doi.org\/10.1016\/s0021-9258(18)65573-5.","journal-title":"J Biol Chem"},{"issue":"5","key":"4554_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jac\/11.5.427","volume":"11","author":"MJ Hall","year":"1983","unstructured":"Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983;11(5):427\u201333. https:\/\/doi.org\/10.1093\/jac\/11.5.427.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4554_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae052","volume":"6","author":"X Qin","year":"2024","unstructured":"Qin X, Ding L, Hao M, Li P, Hu F, Wang M. Antimicrobial resistance of clinical bacterial isolates in China: current status and trends. JAC-Antimicrobial Resistance. 2024;6(2):dlae052. https:\/\/doi.org\/10.1093\/jacamr\/dlae052.","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"3","key":"4554_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. 2019;17(3):141\u201355. https:\/\/doi.org\/10.1038\/s41579-018-0141-x.","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"4554_CR37","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41564-019-0480-z","volume":"4","author":"VI Band","year":"2019","unstructured":"Band VI, Hufnagel DA, Jaggavarapu S, Sherman EX, Wozniak JE, Satola SW, et al. Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection. Nat Microbiol. 2019;4(10):1627\u201335. https:\/\/doi.org\/10.1038\/s41564-019-0480-z.","journal-title":"Nat Microbiol"},{"issue":"8","key":"4554_CR38","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1128\/AAC.00179-13","volume":"57","author":"C Tascini","year":"2013","unstructured":"Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, et al. Synergistic activity of colistin plus Rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57(8):3990\u20133. https:\/\/doi.org\/10.1128\/AAC.00179-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4554_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/QCO.0000000000000109","volume":"27","author":"PI Rafailidis","year":"2014","unstructured":"Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014;27(6):479\u201383. https:\/\/doi.org\/10.1097\/QCO.0000000000000109.","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"4554_CR40","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1128\/AAC.01190-09","volume":"54","author":"CC Bulik","year":"2010","unstructured":"Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2010;54(2):804\u201310. https:\/\/doi.org\/10.1128\/AAC.01190-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4554_CR41","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","volume":"17","author":"GL Daikos","year":"2011","unstructured":"Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17(8):1135\u201341. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03553.x.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4554_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","volume":"41","author":"S Yaghoubi","year":"2022","unstructured":"Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022;41(7):1003\u201322. https:\/\/doi.org\/10.1007\/s10096-020-04121-1.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4554_CR43","doi-asserted-by":"publisher","first-page":"920761","DOI":"10.3389\/fcimb.2022.920761","volume":"12","author":"X Ma","year":"2022","unstructured":"Ma X, Fu S, Wang Y, Zhao L, Yu W, He Y, et al. Proteomics study of the synergistic killing of Tigecycline in combination with aminoglycosides against Carbapenem-Resistant Klebsiella pneumoniae. Front Cell Infect Microbiol. 2022;12:920761. https:\/\/doi.org\/10.3389\/fcimb.2022.920761.","journal-title":"Front Cell Infect Microbiol"},{"key":"4554_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02029","volume":"10","author":"X Ma","year":"2019","unstructured":"Ma X, He Y, Yu X, Cai Y, Zeng J, Cai R, et al. Ceftazidime\/avibactam improves the antibacterial efficacy of polymyxin B against polymyxin B heteroresistant KPC-2-producing Klebsiella pneumoniae and hinders emergence of resistant subpopulation in vitro. Front Microbiol. 2019;10:2029. https:\/\/doi.org\/10.3389\/fmicb.2019.02029.","journal-title":"Front Microbiol"},{"issue":"9","key":"4554_CR45","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1007\/s00253-020-10525-y","volume":"104","author":"J Yin","year":"2020","unstructured":"Yin J, Meng Q, Cheng D, Fu J, Luo Q, Liu Y, et al. Mechanisms of bactericidal action and resistance of polymyxins for Gram-positive bacteria. Appl Microbiol Biotechnol. 2020;104(9):3771\u201380. https:\/\/doi.org\/10.1007\/s00253-020-10525-y.","journal-title":"Appl Microbiol Biotechnol"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04554-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:02:54Z","timestamp":1767834174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-025-04554-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4554"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04554-8","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of Tianjin Medical University General Hospital (NO. IRB2024-YX-415-01) and was conducted in compliance with the principles of the Declaration of Helsinki. We obtained the data from the laboratory information system and analysed the data anonymously. This study was an in vitro study and does not involve humans, informed consent was waived by the Ethics Committee of Tianjin Medical University General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"13"}}